An observational study in Parkinson Disease, sponsored by University Hospital, Ghent. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University Hospital, Ghent · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Parkinson Disease with a site in Belgium — 19 open to participants now, 23 under way, 2 of them phase 3. Parkinson Disease · Belgium.
Among the 82 studies in Parkinson Disease with a site in Belgium, this one is the 16th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2026, is one of 17 observational ones, reaches primary completion later than 9 of the 22 other live ones, and was the 82nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →19 of the 82 studies in Parkinson Disease with a site in Belgium are open now. Recruiting first, the newest first:
University Ghent · Sites in Belgium
Ages 18+
AbbVie · Sites in Belgium
Ages 18+
Loes Laurijssen · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18–90 · Healthy volunteers
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Belgium, Netherlands
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 18 · Phase 4 1
First in 2002; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 52 across the 65 interventional studies, 100 across the 17 observational. Of the 53 that completed or were terminated, 11 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 82 have an industry lead sponsor. The 10 most frequent:
University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 157 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
University Hospital, Ghent has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
8 of the studies in Parkinson Disease with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548801Université Libre de BruxellesCerebellar Transcranial Direct Current Stimulation in Parkinson's Disease | 2026-11 |
| NCT07863219University GhentShort Term Effects of a Multimodal Intervention With RGM on Cognition in People With Parkinson's Disease. | 2026-12-20 |
| NCT06909045Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease | 2027-02-01 |
| NCT06798844Universitaire Ziekenhuizen KU LeuvenSpinal Cord Stimulation for Freezing of Gait in Parkinson's Disease | 2027-05 |
| NCT07863102University Hospital, GhentExtended Reality Rehabilitation in Parkinson's Disease | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 82 studies in Parkinson Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates how different types of extended reality, Virtual Reality (fully immersive) and Mixed Reality (partly real-world), can be used in rehabilitation for people with Parkinson's disease. Participants will attend a single 45-minute session at the Rehabilitation Center of UZ Ghent, where they will perform a simple balloon-popping task twice using a VR headset, once in each environment. During the exercises, they will be safely supported to prevent falls, while a wearable device measures physical responses such as heart rate and skin conductance. After each task, participants will complete short questionnaires about their experience and mental effort. The study aims to determine which type of extended reality is preferred and how each affects physical and mental responses, supporting the development of more accessible rehabilitation approaches.
Extended reality is being used increasingly within neurological rehabilitation. However, there are different forms of extended reality that can be used while wearing a head-mounted display (a VR headset). For example, sometimes the patient no longer sees the environment at all and is thus completely immersed in virtual reality (Virtual Reality), or sometimes the patient still sees part of the environment alongside the virtual reality (Mixed Reality). There are therapeutic arguments for using both forms, but to date, it is not known which is preferred for individuals with Parkinson's disease.
In a previous study (ONZ-2022-0404), a new type of therapy was tested in individuals with Parkinson's disease: visual perturbation training. This study took place in a large VR lab at Ghent University Hospital. To make this therapy accessible to more patients, this study will investigate the effect using a VR headset. Therefore, first the subjective preference in a small group of individuals with Parkinson's disease will be examined, and this study will also investigate whether there is a difference in the use of various forms of extended reality regarding a number of physical parameters (heart rate, heart rate variability, changes in skin conductance, etc.) measured in the patient using a wearable device, as well as mental load via questionnaires.
The participants will perform an exercise twice in which they have to pop balloons in a virtual world (Virtual Reality or Mixed Reality). During the exercise, participants will be secured in the Rysen, a weight-bearing system that ensures the participant cannot fall in the event of loss of balance. After each exercise, participants will complete the questionnaires on Redcap via a tablet provided by the department.
One test session lasts approximately 45 minutes.
All devices used (VR headset, Rysen weight-bearing system to guarantee patient safety, Shimmer to measure heart rate variability and skin conductance) are CE marked and are used within their scope. All tests will take place at the Rehabilitation Center of UZ Ghent. The VR headset and Rysen are devices owned by UZ Ghent. The Shimmer wearable is being made available by UGent for the duration of the study.
This information can help us with targeted follow-up research and applying for the necessary funding.
Parkinson's Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants complete two conditions during a single study session using a head-mounted display, a Virtual Reality (fully immersive) and Mixed Reality (real-world view combined with virtual elements) tasks. The order of conditions is varied. During both conditions, participants perform a standardized balloon-popping task while seated in a weight-support system to ensure safety. Physiological responses (heart rate, heart rate variability, and skin conductance) are recorded, and subjective experience and mental load are assessed via questionnaires after each condition.
Device: Extended reality balance training
Participants perform a balloon-popping task for balance training using a VR headset in two conditions: Virtual Reality (fully immersive) and Mixed Reality (real-world combined with virtual elements). The task includes visual changes to challenge how participants see and respond to their environment, including eye movements. The goal is to compare how these two formats affect mental effort and experience.
Score on the Igroup presence questionnaire (IPQ)
The Igroup Presence Questionnaire (IPQ) is a scale for measuring the sense of presence experienced in a virtual environment. It will be used as one of the measures to identify the subjective preference during Virtual Reality (fully immersive) and Mixed Reality (real-world combined with virtual elements). This questionaire consists of 14 items where participants indicate their spatial presence, involvement or realness on a Likert scale (1-7). Max score is 98. Higher score is higher feeling of presence, immersion and engagement.
Time frame: Immediately after each condition (within one study session)
Score on the NASA Task Load Index (Nasa-TLX)
The NASA-TLX is a questionnaire to examine the subjective workload. It contains 6 items where participants again score each item on a 7 point Likert scale. A higher score indicates more cognitive workload.
Time frame: Immediately after each condition (within one study session)
Score on the Virtual Reality Sickness Questionnaire
Questionnaire to document potential side effects of using extended reality (e.g. cybersickness). Participants are asked to indicate for 9 symptoms on a 4 point Likert scale if they experience side effects and how intense they are present. A higher score indicates more adverse events.
Time frame: Immediately after each condition (within one study session)
Hartrate (variability) during the extended reality sessions
Physiological responses during VR and MR conditions are measured continuously using a wearable device. These measures reflect autonomic nervous system activity and objective load during task performance. Differences between VR and MR conditions will be analyzed.
Time frame: During the MR and VR condition (within one study session)
Skin conduction during the extended reality sessions
Physiological responses during VR and MR conditions are measured continuously using a wearable device. These measures reflect autonomic nervous system activity and objective load during task performance. Differences between VR and MR conditions will be analyzed.
Time frame: During the MR and VR condition (within one study session)
Eye tracking during the extended reality task as a measure of visual function
Exploration of the relationship between visual function and subjective cognitive load scores obtained after the MR condition, to assess whether eye movement behavior contributes to perceived mental effort.
Time frame: During the MR session
Education level
Participants will be questioned to know their highest education level. This will be used to assess if this a co-variate for the primary outcome measures
Time frame: Before the intervention
Experience with the use of extended reality
Participants will be questioned to know if they have any experience using extended reality. This will be used to assess if this a co-variate for the primary outcome measures
Time frame: Before the intervention
Technological skilled
Participants will be questioned to know if they consider themselves technological skilled. This will be used to assess if this a co-variate for the primary outcome measures
Time frame: Before the intervention
Start is estimated for Oct 2026; primary completion for May 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.